VRAX
Virax Biolabs Group·NASDAQ
--
--(--)
--
--(--)
3.54 / 10
Netural
Fund‑flow rating is good (7.08/10) with modest inflow ratios (~0.46) but negative trends across all investor sizes. Analyst view is overwhelmingly bullish (100% Strong Buy) yet the sole analyst has a 0% historical win rate and –17% average return, suggesting caution.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for VRAX?
- VRAX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.54/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
